Todas las investigaciones
Activo, no reclutandoFASE2INTERVENCIONISTA

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

This study is investigating a new medication, elafibranor, for adults who have a rare liver disease called Primary Sclerosing Cholangitis (PSC). PSC causes damage to the small tubes in the liver that carry a fluid called bile. Over time, this damage can worsen the liver condition. The study aims to understand if elafibranor is safe to use and what side effects it might have. We will also carefully check if the medicine helps improve aspects of PSC, using blood tests and other assessments. Some participants will receive elafibranor, while others will get a placebo (a dummy treatment) to help us compare the effects fairly.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE2
Patrocinador
Ipsen
Objetivo de inscripción
68
Inicio
29 Dic 2022
Estimación de finalización
23 Sep 2031

¿De qué trata este estudio?

This research study is about a new medicine called elafibranor for a liver disease known as Primary Sclerosing Cholangitis, or PSC. PSC is a rare condition where the small tubes inside your liver, called bile ducts, get damaged and scarred. These bile ducts are important because they carry bile, a fluid that helps digest food, from your liver. When they get damaged, bile can build up in the liver, which can cause more damage over time and make the disease worse.

The main goal of this study is to find out if elafibranor is safe for people with PSC and what its side effects might be. We also want to see if this medicine can help improve the condition by looking at certain blood tests and other checks related to PSC activity. To do this, some people will receive elafibranor, while others will get a 'placebo', which looks exactly like the study medicine but contains no active drug. This helps us understand if any changes are truly due to the medicine or something else.

Taking part in a study like this helps doctors learn more about diseases like PSC and develop new treatments. It's an important step in finding better ways to manage the condition and improve the lives of people living with it.

Puntos clave

  • This study is for adults with a rare liver condition called Primary Sclerosing Cholangitis (PSC).
  • It's testing a new medicine, elafibranor, to see if it's safe and helpful.
  • Some participants will receive the study medicine, others a placebo (dummy treatment).
  • You'll have regular hospital or clinic visits for blood tests and checks.
  • The study aims to improve understanding and treatment options for PSC.
  • La participación es voluntaria, y puedes retirarte en cualquier momento.

¿Quién puede ser elegible?

This study is looking for adults aged between 18 and 75 who have been diagnosed with Primary Sclerosing Cholangitis (PSC). To join, you should have clear medical evidence of PSC from scans and blood tests, and your PSC should not be due to other known causes.

There are also specific requirements for your blood test results, particularly for liver health markers like Alkaline Phosphatase (ALP) and total bilirubin, which need to be within certain ranges. If you are taking medication for PSC, like ursodeoxycholic acid (UDCA), it needs to have been at a steady dose for at least six months. If you recently stopped UDCA, you'd need to have been off it for at least three months before the study starts.

If you also have Inflammatory Bowel Disease (IBD), such as Crohn's disease or ulcerative colitis, it needs to be well-controlled and stable on your current treatment for at least three months. You would also need to have had a colonoscopy within the past year with no signs of serious changes. There are also considerations for other medications you might be taking to manage PSC symptoms like itching.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes entre 18 y 75 años?
  2. Have you been diagnosed with Primary Sclerosing Cholangitis (PSC)?
  3. Do your recent blood tests for liver function meet certain requirements?
  4. If you take UDCA, has your dose been stable for at least 6 months (or off for 3 months)?
  5. If you have Inflammatory Bowel Disease (IBD), is it well-controlled?
  6. Have you had a colonoscopy within the last year with no signs of serious changes (if you have IBD)?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join this study, you'll be assigned to take either one of two doses of elafibranor (80mg or 120mg) or a placebo (a dummy treatment) in pill form. You will take this medication daily. You'll have regular visits to the hospital or clinic for check-ups, blood tests, and other assessments to monitor your health and how you're responding to the treatment. These tests will include checking your liver function and overall well-being. The study will involve a main treatment period, followed by a period where your health continues to be monitored. The total duration of your participation, including follow-up, will be explained in detail by the study team.

Riesgos y beneficios potenciales

Taking part in a research study has potential benefits and risks. You might not directly benefit from taking elafibranor, as it's an investigational medicine, but the information gained from the study could help future patients with PSC. Potential risks include side effects from the study drug, which will be carefully monitored. The study team will explain all known potential side effects and what to look out for. You will also have additional blood tests and check-ups. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (62)

  • Om Research LLC
    Código postal verificado
    Lancaster, United States
  • Cedars-Sinai Medical Center
    Código postal verificado
    Los Angeles, United States
  • University of California, Davis
    Código postal verificado
    Sacramento, United States
  • Sutter Health Van Ness Campus Medical Office Building
    Código postal verificado
    San Francisco, Estados Unidos
  • Peak Gastroenterology Associates
    Código postal verificado
    Colorado Springs, Estados Unidos
  • South Denver Gastroenterology,P.C.
    Código postal verificado
    Englewood, United States
  • Rocky Mountain Gastroenterology (RMG)
    Código postal verificado
    Littleton, United States
  • Yale University School Of Medicine - Yale Center For Clinical Investigation
    Código postal verificado
    New Haven, Estados Unidos
  • Schiff Center for Liver Diseases - University of Miami
    Código postal verificado
    Miami, United States
  • Covenant Research
    Código postal verificado
    Sarasota, United States
  • Piedmont Hospital - Piedmont Transplant Institute
    Código postal verificado
    Atlanta, Estados Unidos
  • Tandem Clinical Research GI
    Código postal verificado
    Marrero, United States

Preguntas comunes

What is Primary Sclerosing Cholangitis (PSC)?

PSC is a rare liver disease where the bile ducts (small tubes in your liver) become damaged, leading to bile build-up and liver damage.

What is elafibranor?

Elafibranor is the study medicine being tested to see if it can help people with PSC. It's a new drug not yet widely available.

¿Qué es un placebo?

A placebo is a 'dummy' pill that looks just like the study medicine but doesn't contain any active drug. It helps us compare the effects of the actual medicine.

Will I know if I'm getting the active drug or the placebo?

No, during the main part of the study, neither you nor your doctor will know if you are receiving elafibranor or the placebo. This is called 'blinding' and helps ensure fair results.

¿Cuánto tiempo estaré en el estudio?

The total length of your time in the study will be discussed by the research team. It includes a period of taking the medicine and follow-up checks.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.